Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA cystic fibrosis (CF) program through three ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) reported a fourth quarter loss of $1.03 per share and revenue of $7.2 million, as the messenger RNA medicines company ...
Arcturus Therapeutics (NASDAQ: ARCT) is gearing up to announce its quarterly earnings on Tuesday, 2026-03-03. Here's a quick ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today ...
Here are 9 thing to know about the variant, according to AdventHealth: 1. According to health officials, COVID-19 is still a leading cause of death around the world, including in the United States ...
Face east around 9-9:30 p.m. in mid-April and you can't miss shimmering orange Arcturus, the brightest star in the constellation Bootes the Bear Guardian. Two fists to the lower left of Arcturus, look ...
Arcturus' mRNA vaccine will be trying to break into a crowded market if it gets approved. Moderna was in the right place at the right time, and Arcturus isn't. Yet, Arcturus doesn't need to sell many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results